ABCC6 is involved in the resistance to several anticancer agents, including etoposide, doxorubicin, and daunorubicin [10], and its up-regulation appears to contribute to gemcitabine resistance in human non-small-cell lung cancer and to Nilotinib and Dasatinib resistance in both chronic myeloid leukemia cell lines and primary patient mononuclear cells [11,12]. Here, ABCC6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.